Overview

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
Phase:
Phase 3
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Takeda Pharmaceuticals North America, Inc.
Treatments:
Citalopram
Dexetimide